Literature DB >> 910613

Parenteral use of diazepam in an emulsion formulation. A clinical study.

A M Thorn-Alquist.   

Abstract

A recently described injection formulation for diazepam, consisting of an oil emulsion where the drug is dissolved in the oil phase, has been found to give a lessened degree of side reactions than commercially available preparations. This emulsion formulation was compared to Valium inj. as premedication in patients undergoing operation for hernia or varices under epidural anaesthesia. The effects, measured as the degree of drowsiness according to an arbitrary scale, were found to be equal for the two formulations. Neither was there any difference in blood concentrations in the two application groups, respectively, between the preparations used. The propylene glycol content of Valium inj. is said to cause a delayed release of the drug from the injection site after i.m. application, and this is briefly discussed, as well as the possibility of administering the diazepam emulsion continuously, diluted with Intralipid, without the risk of precipitation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 910613     DOI: 10.1111/j.1399-6576.1977.tb01239.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion.

Authors:  Y Wang; G M Mesfin; C A Rodríguez; J G Slatter; M R Schuette; A L Cory; M J Higgins
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Drug efficacy and side effects following different formulations of intravenous diazepam.

Authors:  M Craig; J F Fielding
Journal:  Ir J Med Sci       Date:  1982-03       Impact factor: 1.568

3.  A prospective randomised controlled trial of diazepam (valium) vs emulsified diazepam (diazemuls) as a premedication for upper gastrointestinal endoscopy.

Authors:  D Gleeson; J D Rose; P M Smith
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.